newsfilter
← Latest News
GlobeNewswire·

Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results

Q4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment)Q4 and FY Thyroid